[{"id":"28ed5efa-c5b5-4262-aa3e-54b883b60ead","acronym":"ARTISTRY-3","url":"https://clinicaltrials.gov/study/NCT04592653","created_at":"2021-01-19T20:28:47.499Z","updated_at":"2024-07-02T16:34:37.223Z","phase":"Phase 1/2","brief_title":"Less Frequent IV Dosing \u0026 Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","source_id_and_acronym":"NCT04592653 - ARTISTRY-3","lead_sponsor":"Mural Oncology, Inc","biomarkers":" MSI • NCAM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-07"},{"id":"99a01e3b-69fe-427a-baac-ef5a7f10f3fb","acronym":"LIGHTSPEED-1","url":"https://clinicaltrials.gov/study/NCT06277219","created_at":"2024-02-26T15:26:48.540Z","updated_at":"2024-07-02T16:34:37.776Z","phase":"Phase 1/2","brief_title":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","source_id_and_acronym":"NCT06277219 - LIGHTSPEED-1","lead_sponsor":"Latticon Antibody Therapeutics, Inc","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-06"},{"id":"e17dace3-40cf-43d5-bbae-779980aa63c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02938299","created_at":"2022-04-11T23:53:12.156Z","updated_at":"2024-07-02T16:35:10.976Z","phase":"Phase 3","brief_title":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","source_id_and_acronym":"NCT02938299","lead_sponsor":"Philogen S.p.A.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nidlegy (darleukin/fibromun) • darleukin (L19IL2)"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"3acfa9f6-10ca-4b1d-bfea-249843456580","acronym":"ARTISTRY-6","url":"https://clinicaltrials.gov/study/NCT04830124","created_at":"2021-04-02T11:53:53.927Z","updated_at":"2024-07-02T16:35:13.615Z","phase":"Phase 2","brief_title":"Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6","source_id_and_acronym":"NCT04830124 - ARTISTRY-6","lead_sponsor":"Mural Oncology, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemvaleukin alfa (ALKS 4230)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-20"}]